ImmusanT Competitors and Similar CompaniesClear all
ImmusanT's competitors and similar companies include Sanesco, Mesoblast, Harmony Biosciences and Translational Sciences.
 ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. |  Sanesco Sanesco Health International is a biomedical company providing healthcare practitioners with clinical tools and products used for neuroendocrine health. |  Mesoblast Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. |  Harmony Biosciences Harmony Biosciences develops therapies to help patients with unmet medical needs. |  Translational Sciences Translational Sciences is a biotechnology company that develops therapeutics for treating acute thrombotic cardiovascular diseases and ischemic stroke. | |
Founding Date | Founding Date 2010 | Founding Date 2004 | Founding Date 2004 | Founding Date 2017 | Founding Date 2007 |
Type | Type Private | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Arden, US HQ | Locations Melbourne, AU HQ Singapore, SG New York, US | Locations Plymouth Meeting, US HQ | Locations Phoenix, US HQ |
Employees | Employees 2 | Employees 23 | Employees 73 | Employees N/A | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) 2.4 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $17.2m (FY, 2025) | Revenue (est.) $868.5m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $1.2m (FY, 2025) | Cost of goods $198.3m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $16.1m (FY, 2025) | Gross profit $670.1m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income N/A | Net income ($102.1m) (FY, 2025) | Net income $158.7m (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 72.8m | Total funding raised N/A | Total funding raised $ 56.2m | Total funding raised $ 270m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sanesco
HQ
Arden, US
Employees
23
Sanesco Health International is a biomedical company providing healthcare practitioners with clinical tools and products used for neuroendocrine health.
View companyMesoblast
HQ
Melbourne, AU
Employees
73
Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine.
View companyHarmony Biosciences
HQ
Plymouth Meeting, US
Harmony Biosciences develops therapies to help patients with unmet medical needs.
View companyTranslational Sciences
HQ
Phoenix, US
Translational Sciences is a biotechnology company that develops therapeutics for treating acute thrombotic cardiovascular diseases and ischemic stroke.
View company